[go: up one dir, main page]

LT3356385T - Prostatos specifinio membranos antigeno (psma) inhibitoriai, žymėti 18f ir jų panaudojimas kaip vaizdinimo agentų prostatos vėžio atveju - Google Patents

Prostatos specifinio membranos antigeno (psma) inhibitoriai, žymėti 18f ir jų panaudojimas kaip vaizdinimo agentų prostatos vėžio atveju

Info

Publication number
LT3356385T
LT3356385T LTEP16778680.5T LT16778680T LT3356385T LT 3356385 T LT3356385 T LT 3356385T LT 16778680 T LT16778680 T LT 16778680T LT 3356385 T LT3356385 T LT 3356385T
Authority
LT
Lithuania
Prior art keywords
psma
imaging agents
specific membrane
membrane antigen
prostate
Prior art date
Application number
LTEP16778680.5T
Other languages
English (en)
Inventor
Jens CARDINALE
Martin Schäfer
Klaus Kopka
Matthias Eder
Ulrike Bauder-Wuest
Michael Eisenhut
Martina Benesova
Uwe Haberkorn
Frederik L. Giesel
Original Assignee
Deutsches Krebsforschungszentrum
Ruprecht-Karls-Universität Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universität Heidelberg filed Critical Deutsches Krebsforschungszentrum
Publication of LT3356385T publication Critical patent/LT3356385T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • G01N33/57555
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
LTEP16778680.5T 2015-09-30 2016-09-19 Prostatos specifinio membranos antigeno (psma) inhibitoriai, žymėti 18f ir jų panaudojimas kaip vaizdinimo agentų prostatos vėžio atveju LT3356385T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15002800 2015-09-30
EP16164090 2016-04-06
EP16182764 2016-08-04
PCT/EP2016/001573 WO2017054907A1 (en) 2015-09-30 2016-09-19 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer

Publications (1)

Publication Number Publication Date
LT3356385T true LT3356385T (lt) 2021-02-25

Family

ID=57121178

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16778680.5T LT3356385T (lt) 2015-09-30 2016-09-19 Prostatos specifinio membranos antigeno (psma) inhibitoriai, žymėti 18f ir jų panaudojimas kaip vaizdinimo agentų prostatos vėžio atveju

Country Status (31)

Country Link
US (3) US10815200B2 (lt)
EP (2) EP3805250A1 (lt)
JP (1) JP6824971B2 (lt)
KR (1) KR102233726B1 (lt)
CN (1) CN108026144B (lt)
AU (1) AU2016333334B2 (lt)
BR (1) BR112018005899A2 (lt)
CL (1) CL2018000604A1 (lt)
CO (1) CO2018003726A2 (lt)
CU (1) CU24524B1 (lt)
CY (1) CY1123790T1 (lt)
DK (1) DK3356385T3 (lt)
EA (1) EA037512B1 (lt)
ES (1) ES2844586T3 (lt)
GE (2) GEAP202014748A (lt)
HR (1) HRP20210183T1 (lt)
HU (1) HUE053064T2 (lt)
IL (1) IL258378B (lt)
LT (1) LT3356385T (lt)
MX (1) MX390931B (lt)
MY (1) MY197061A (lt)
NZ (1) NZ739770A (lt)
PE (1) PE20181350A1 (lt)
PH (1) PH12018500701B1 (lt)
PL (1) PL3356385T3 (lt)
RS (1) RS61394B1 (lt)
SA (1) SA518391121B1 (lt)
SI (1) SI3356385T1 (lt)
TN (1) TN2018000089A1 (lt)
WO (1) WO2017054907A1 (lt)
ZA (1) ZA201801024B (lt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805250A1 (en) * 2015-09-30 2021-04-14 Deutsches Krebsforschungszentrum Improved 18f - tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
BR112019002560B1 (pt) 2016-08-10 2022-08-16 Cancer Targeted Technology Llc Composto, composição farmacêutica, seus usos e método de preparação do mesmo
US10340046B2 (en) 2016-10-27 2019-07-02 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
DE102016122273B4 (de) * 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung
WO2018098390A1 (en) * 2016-11-23 2018-05-31 Cancer Targeted Technology Llc Albumin-binding psma inhibitors
CN113710159B (zh) 2019-04-24 2026-01-13 普罗热尼奇制药公司 用于对骨扫描图像进行自动化及交互式分析以检测转移的系统及方法
CN110272468B (zh) * 2019-05-14 2020-12-08 上海益泰医药科技有限公司 一种前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用
US12417533B2 (en) 2019-09-27 2025-09-16 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
CN111253465A (zh) * 2020-03-03 2020-06-09 复旦大学附属肿瘤医院 一种psma结合剂及其用途
CA3206250A1 (en) 2021-02-08 2022-08-11 Mark RIJPKEMA Psma-targeting ligands for multimodal applications
US20240293586A1 (en) 2021-07-30 2024-09-05 Osaka University Radiolabeled compound and use thereof
CN117615795A (zh) * 2021-09-01 2024-02-27 天津恒瑞医药有限公司 前列腺特异性膜抗原的抑制剂及其医药用途
CN118344391A (zh) * 2023-01-13 2024-07-16 浙江普利药业有限公司 一种新的用于硼中子捕获疗法的含硼化合物
US20250213705A1 (en) * 2023-08-23 2025-07-03 Bright Peak Therapeutics Ag Psma targeting ligands and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479470B1 (en) 1999-04-28 2002-11-12 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALAdase
EP1409017A4 (en) 2001-06-25 2006-05-24 Drug Innovation & Design Inc CELL TARGETING INVOLVING THE RECONNAISSANCE OF EXPONENTIAL FORMS, COMPOSITIONS, METHODS AND ANTICANCER APPLICATIONS
CA2473289C (en) 2002-01-10 2014-07-29 The Johns Hopkins University Asymmetric urea compounds useful as naaladase and psma imaging agents
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
EP2087337A4 (en) 2006-11-03 2010-09-08 Purdue Research Foundation METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY
ES2547481T3 (es) 2006-11-08 2015-10-06 Molecular Insight Pharmaceuticals, Inc. Heterodímeros de ácido glutámico
CA2675202C (en) 2007-01-11 2014-09-16 Immunomedics, Inc. Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
AU2008269094B2 (en) 2007-06-26 2015-04-09 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
EP3838298B1 (en) * 2007-08-17 2025-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
HUE035101T2 (hu) 2007-09-28 2018-05-02 Pfizer Ráksejtek célzása nanorészecskék alkalmazásával
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
CN102083427B (zh) 2008-01-09 2014-12-10 分子洞察制药公司 碳酸酐酶ix的抑制剂
HRP20171133T1 (hr) 2008-08-01 2017-10-20 The Johns Hopkins University Psma-vezujući agensi i njihove uporabe
WO2010065899A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
CN102272100B (zh) * 2008-12-05 2016-08-17 分子制药洞察公司 用于抑制psma的锝-和铼-双(杂芳基)络合物及其使用方法
EP3222617B1 (en) 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
GB0905438D0 (en) 2009-03-30 2009-05-13 Ge Healthcare Ltd Radiolabelling reagents and methods
EP2338892A1 (en) * 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostate specific membrane antigen inhibitors
GB201020314D0 (en) 2010-12-01 2011-01-12 Ge Healthcare Ltd Apoptosis pet imaging agents
ES2675320T3 (es) 2010-12-06 2018-07-10 Molecular Insight Pharmaceuticals, Inc. Dendrímeros dirigidos a PSMA
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
AU2012294639B2 (en) 2011-08-05 2017-10-26 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
WO2013028664A1 (en) * 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
CN110179995A (zh) 2012-12-28 2019-08-30 塔弗达治疗有限公司 包封在颗粒中的靶向缀合物及其制剂
US9889199B2 (en) 2013-02-15 2018-02-13 Case Western Reserve University PSMA ligands and uses thereof
WO2015004029A1 (en) 2013-07-08 2015-01-15 Technische Universität München 18f-labeling of aromatic and heteroaromatic molecules with unprotected carboxylic acid groups
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
WO2015057250A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
EP3415489A1 (en) * 2013-10-18 2018-12-19 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
SG10201803618RA (en) 2013-11-14 2018-06-28 Endocyte Inc Compounds for positron emission tomography
WO2015143029A1 (en) 2014-03-18 2015-09-24 The Johns Hopkins University Psma-based molecular-genetic reporter system
CA2950892C (en) 2014-05-06 2023-10-24 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
PL3183236T3 (pl) 2014-08-24 2022-07-18 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Sposób wytwarzania 18f-znakowanych aktywnych estrów i ich zastosowanie na przykładzie wytwarzania znacznika pet specyficznego dla psma
US9956305B2 (en) 2014-09-08 2018-05-01 Molecular Insight Pharmaceuticals, Inc. Organ protection in PSMA-targeted radionuclide therapy of prostate cancer
WO2016062370A1 (en) * 2014-10-20 2016-04-28 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3011976A1 (en) 2014-10-20 2016-04-27 Deutsches Krebsforschungszentrum 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents
WO2016065142A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University New scaffolds and multifunctional intermediates for imaging psma and cancer therapy
EP3805250A1 (en) * 2015-09-30 2021-04-14 Deutsches Krebsforschungszentrum Improved 18f - tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer

Also Published As

Publication number Publication date
HRP20210183T1 (hr) 2021-04-30
ZA201801024B (en) 2019-06-26
CO2018003726A2 (es) 2018-07-19
WO2017054907A1 (en) 2017-04-06
EP3356385A1 (en) 2018-08-08
US10815200B2 (en) 2020-10-27
MY197061A (en) 2023-05-23
CA2996330A1 (en) 2017-04-06
US20180194729A1 (en) 2018-07-12
GEP20207106B (en) 2020-05-11
BR112018005899A2 (pt) 2018-10-16
ES2844586T3 (es) 2021-07-22
IL258378B (en) 2021-03-25
NZ739770A (en) 2019-07-26
EP3356385B1 (en) 2020-11-11
CN108026144B (zh) 2022-02-01
MX2018004050A (es) 2018-08-01
US20230295092A1 (en) 2023-09-21
SI3356385T1 (sl) 2021-04-30
AU2016333334A1 (en) 2018-03-08
PL3356385T3 (pl) 2021-06-28
KR20180058822A (ko) 2018-06-01
JP6824971B2 (ja) 2021-02-03
RS61394B1 (sr) 2021-02-26
PH12018500701A1 (en) 2018-10-15
PE20181350A1 (es) 2018-08-22
DK3356385T3 (da) 2021-02-15
SA518391121B1 (ar) 2021-05-30
CU20180030A7 (es) 2018-08-06
MX390931B (es) 2025-03-21
PH12018500701B1 (en) 2022-11-16
CU24524B1 (es) 2021-06-08
GEAP202014748A (en) 2020-01-27
EA201890282A1 (ru) 2018-09-28
EA037512B1 (ru) 2021-04-06
AU2016333334B2 (en) 2019-07-25
KR102233726B1 (ko) 2021-03-31
JP2018531243A (ja) 2018-10-25
CN108026144A (zh) 2018-05-11
US12054458B2 (en) 2024-08-06
TN2018000089A1 (en) 2019-07-08
CY1123790T1 (el) 2022-05-27
US20210053922A1 (en) 2021-02-25
EP3805250A1 (en) 2021-04-14
HUE053064T2 (hu) 2021-06-28
CL2018000604A1 (es) 2019-03-29
IL258378A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
HUS2400024I1 (hu) A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
LT3356385T (lt) Prostatos specifinio membranos antigeno (psma) inhibitoriai, žymėti 18f ir jų panaudojimas kaip vaizdinimo agentų prostatos vėžio atveju
IL260342A (en) Urea-based prostate membrane-specific antigen suppressor for imaging and therapy
CY1126819T1 (el) Σημασμενοι αναστολεις ειδικου προστατικου αντιγονου μεμβρανης (psma), η χρηση τους ως παραγοντες απεικονισης και φαρμακευτικοι παραγοντες για την αντιμετωπιση του καρκινου του προστατη
IL272274A (en) B7-h4 antibodies and methods of use thereof
LT3183268T (lt) Anti-cd123 chimerinis antigeno receptorius (car), skirtas naudoti vėžio gydymui
IL252796B (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
IL250043A0 (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
SI3925952T1 (sl) Za prostato specifična, na membranski antigen usmerjena visoko afinitetna sredstva za endoradioterapijo raka prostate
DK3126390T3 (da) Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi
HUE046505T2 (hu) Antitestkészítmények daganatkezelésre
SI3129470T1 (sl) Zdravljenje raka z uporabo antigenskega himernega receptorja proti-cd19
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
LT2958943T (lt) Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
DK3116911T3 (da) Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
DK3113797T3 (da) Antistoffer, anvendelser og fremgangsmåder
LT3386997T (lt) Monomaleimidu funkcionalizuoti platinos junginiai, skirti vėžio terapijai
EP3177298A4 (en) Methods for treating inflammatory bowel disease using prostate specific membrane antigen (psma) inhibitors
LT3405213T (lt) Bakteriniai šešėliai, skirti panaudoti vėžio gydyme
DK3344287T3 (da) Anti-survivin-antistoffer til cancerterapi
DK3795130T3 (da) Terapiapparat.
DK3643707T3 (da) 18f-mærket forbindelse til diagnosticering af prostatkræft, og anvendelse deraf
PT3356385T (pt) Inibidores etiquetados com 18f de antigénio de membrana específico de próstata (psma) e utilização dos mesmos como agentes de imagiologia para o cancro da próstata
TH1601003749A (th) แอนทิบอดีชนิดโมโนคลอนัลที่ทำให้เป็นกลาง แอนทิ-il-33 ของมนุษย์